Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JANX Janux Therapeutics	$26.40 -4.9%	$24.62	$22.48 ▼ $71.71	$1.56B	2.86	878,789 shs	908,736 shs
OCUL Ocular Therapeutix	$11.33 -0.4%	$8.80	$5.79 ▼ $11.78	$1.80B	1.43	1.44 million shs	2.13 million shs
SNDL SNDL	$1.54 -1.3%	$1.32	$1.15 ▼ $2.40	$404.68M	3.4	1.96 million shs	2.41 million shs
VERA Vera Therapeutics	$23.05 -3.0%	$22.78	$18.53 ▼ $51.61	$1.47B	1.19	1.00 million shs	756,175 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JANX Janux Therapeutics	0.00%	+4.97%	+16.20%	-11.08%	-39.88%
OCUL Ocular Therapeutix	0.00%	+2.72%	+36.01%	+54.99%	+41.63%
SNDL SNDL	0.00%	+10.79%	+21.26%	+10.00%	-29.36%
VERA Vera Therapeutics	0.00%	-3.23%	+10.18%	+8.27%	-34.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
JANX Janux Therapeutics	2.2628 of 5 stars	3.5	1.0	0.0	3.0	2.5	0.0
OCUL Ocular Therapeutix	3.6437 of 5 stars	3.5	2.0	4.1	0.6	2.5	0.0
SNDL SNDL	1.1195 of 5 stars	2.0	3.0	0.0	0.0	0.0	1.3
VERA Vera Therapeutics	4.0713 of 5 stars	4.6	5.0	0.0	1.9	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JANX Janux Therapeutics	3.08	Buy	$91.89	248.06% Upside
OCUL Ocular Therapeutix	3.00	Buy	$17.33	52.99% Upside
SNDL SNDL	0.00	N/A	$4.00	159.74% Upside
VERA Vera Therapeutics	3.10	Buy	$65.00	182.00% Upside

Current Analyst Ratings Breakdown

Latest SNDL, JANX, OCUL, and VERA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	JANX Janux Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
6/3/2025	VERA Vera Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/3/2025	VERA Vera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/2/2025	VERA Vera Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Sector Outperform ➝ Sector Outperform	$55.00 ➝ $65.00
6/2/2025	VERA Vera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $85.00
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
5/7/2025	VERA Vera Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$34.00 ➝ $26.00
5/7/2025	VERA Vera Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$107.00 ➝ $100.00
5/6/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
5/5/2025	VERA Vera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$75.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JANX Janux Therapeutics	$10.59M	147.51	N/A	N/A	$19.49 per share	1.35
OCUL Ocular Therapeutix	$63.72M	28.33	N/A	N/A	$2.01 per share	5.64
SNDL SNDL	$927.61M	0.44	N/A	N/A	$3.15 per share	0.49
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$9.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JANX Janux Therapeutics	-$68.99M	-$1.36	N/A	N/A	N/A	N/A	-9.29%	-8.89%	8/6/2025 (Estimated)
OCUL Ocular Therapeutix	-$193.51M	-$1.15	N/A	N/A	N/A	-323.09%	-59.92%	-41.98%	8/6/2025 (Estimated)
SNDL SNDL	-$69.18M	-$0.29	N/A	N/A	N/A	-11.48%	-9.02%	-7.60%	7/31/2025 (Estimated)
VERA Vera Therapeutics	-$152.15M	-$3.00	N/A	N/A	N/A	N/A	-40.59%	-34.54%	8/6/2025 (Estimated)

Latest SNDL, JANX, OCUL, and VERA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	VERA Vera Therapeutics	-$0.82	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	JANX Janux Therapeutics	-$0.50	N/A	N/A	N/A	$0.30 million	N/A
8/6/2025	Q2 2025	OCUL Ocular Therapeutix	-$0.35	N/A	N/A	N/A	$13.12 million	N/A
7/31/2025	Q2 2025	SNDL SNDL	-$0.04	N/A	N/A	N/A	$231.50 million	N/A
5/8/2025	Q1 2025	JANX Janux Therapeutics	-$0.43	-$0.38	+$0.05	-$0.38	$0.59 million	N/A
5/8/2025	Q1 2025	VERA Vera Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	N/A	N/A
5/1/2025	Q1 2025	SNDL SNDL	-$0.06	-$0.04	+$0.02	-$0.04	$214.60 million	$142.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
SNDL SNDL	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JANX Janux Therapeutics	N/A	58.47	58.47
OCUL Ocular Therapeutix	0.26	10.22	10.14
SNDL SNDL	0.10	4.62	3.12
VERA Vera Therapeutics	0.10	27.68	27.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JANX Janux Therapeutics	75.39%
OCUL Ocular Therapeutix	59.21%
SNDL SNDL	N/A
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
JANX Janux Therapeutics	8.10%
OCUL Ocular Therapeutix	2.30%
SNDL SNDL	N/A
VERA Vera Therapeutics	16.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JANX Janux Therapeutics	30	59.17 million	54.38 million	Optionable
OCUL Ocular Therapeutix	230	159.30 million	155.64 million	Optionable
SNDL SNDL	2,516	262.78 million	N/A	Optionable
VERA Vera Therapeutics	40	63.77 million	53.38 million	Optionable

SNDL, JANX, OCUL, and VERA Headlines

Recent News About These Companies

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $65.00 Consensus PT from Analysts

July 18 at 2:37 AM | americanbankingnews.com

Startup targets orphan kidney disease with former Merck drug

July 17 at 2:38 PM | medcitynews.comM

Reviewing Celcuity (NASDAQ:CELC) and Vera Therapeutics (NASDAQ:VERA)

July 16, 2025 | americanbankingnews.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of "Buy" from Brokerages

July 15, 2025 | marketbeat.com

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 10, 2025 | globenewswire.com

Vera Therapeutics Reports Positive Phase 3 ORIGIN Trial Results for Atacicept in IgA Nephropathy

July 6, 2025 | msn.com

Vera Therapeutics Inc Class A Sustainability - Morningstar

July 5, 2025 | morningstar.comM

Vera Therapeutics director Enright buys shares worth $5.2m

June 27, 2025 | investing.com

Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in Funding

June 27, 2025 | msn.com

Vera Therapeutics (NASDAQ:VERA) Shares Gap Up Following Insider Buying Activity

June 26, 2025 | marketbeat.com

Insider Buying: Vera Therapeutics, Inc. (NASDAQ:VERA) Director Acquires 40,607 Shares of Stock

June 26, 2025 | insidertrades.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Purchases 40,607 Shares

June 25, 2025 | marketbeat.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Acquires 209,393 Shares

June 25, 2025 | marketbeat.com

Polycythemia Vera Market Set for Strong Growth Across Key Markets, Backed by Emerging Treatments and Epidemiological Trends | DelveInsight

June 24, 2025 | theglobeandmail.com

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight

June 24, 2025 | finance.yahoo.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Buy" by Brokerages

June 20, 2025 | marketbeat.com

J.P. Morgan Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

June 19, 2025 | theglobeandmail.com

Analysts Can't Get Enough of These Little-Known Biopharma Stocks (VERA)

...

June 12, 2025 | marketbeat.com

Vera Therapeutics Inc.

June 10, 2025 | barrons.com

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 9, 2025 | globenewswire.com

Otsuka, Vera stake their claims to IgAN treatment

June 9, 2025 | pharmaphorum.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDL, JANX, OCUL, and VERA Company Descriptions

Janux Therapeutics NASDAQ:JANX

$26.40 -1.35 (-4.86%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$26.40 +0.01 (+0.02%)

As of 07/18/2025 06:53 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Ocular Therapeutix NASDAQ:OCUL

$11.33 -0.05 (-0.44%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$11.63 +0.30 (+2.68%)

As of 07/18/2025 05:20 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

SNDL NASDAQ:SNDL

$1.54 -0.02 (-1.28%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.54 0.00 (0.00%)

As of 07/18/2025 07:50 PM Eastern

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

Vera Therapeutics NASDAQ:VERA

$23.05 -0.71 (-2.99%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$23.04 0.00 (-0.02%)

As of 07/18/2025 07:52 PM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time